Volume | 738,155 |
|
|||||
News | - | ||||||
Day High | 233.16 | Low High |
|||||
Day Low | 230.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Becton Dickinson and Company | BDX | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
230.00 | 230.00 | 233.16 | 231.55 | 230.48 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
18,296 | 738,155 | US$ 231.44 | US$ 170,836,608 | - | 229.395 - 287.32 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:52:46 | 3 | US$ 231.06 | USD |
Becton Dickinson and Company Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
66.9B | 288.90M | - | 19.37B | 1.42B | 4.93 | 46.98 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Becton Dickinson News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BDX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 234.70 | 236.175 | 230.00 | 233.36 | 899,783 | -3.15 | -1.34% |
1 Month | 247.48 | 247.81 | 229.395 | 238.13 | 1,054,464 | -15.93 | -6.44% |
3 Months | 244.67 | 248.42 | 229.395 | 239.34 | 1,308,838 | -13.12 | -5.36% |
6 Months | 254.48 | 259.96 | 229.395 | 239.12 | 1,520,082 | -22.93 | -9.01% |
1 Year | 258.43 | 287.32 | 229.395 | 249.81 | 1,345,544 | -26.88 | -10.40% |
3 Years | 255.99 | 287.32 | 215.90 | 248.81 | 1,289,476 | -24.44 | -9.55% |
5 Years | 238.51 | 287.32 | 197.75 | 247.62 | 1,379,366 | -6.96 | -2.92% |
Becton Dickinson Description
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business. |